P

Pfizer

Makes cancer drugs, vaccines and other medicines

Field Medical Affairs Scientist: Amyloidosis

Full-Time
No salary listed
Mid
Bachelor's, Master's, PhD, Associate's, MD
Tokyo, Japan
RemoteField-based remote role.
Biology & Biotech

About the job

Requirements
  • A four-year university undergraduate degree and a master's degree in life science, or one of the specified alternate qualifications: a pharmacist with a four-year university degree and a master's degree or above or equivalent life science research experience; a pharmacist with a six-year university degree; a nurse with a master's degree or above; a veterinarian; a dentist; or an MD.
  • Medical and pharmaceutical expert knowledge of the therapeutic disease area and products.
  • Ability to communicate appropriately and build good relationships with internal and external stakeholders.
  • Ability to work effectively with teams and across functions, demonstrate Pfizer's Values & Behaviors, and learn from others.
  • Ability to conduct medical discussions with relevant departments and external healthcare professionals.
  • Understanding of compliance and relevant laws and regulations in the pharmaceutical industry, and ability to advocate appropriate product use.
  • Knowledge and understanding of the internal organization structure, key stakeholders, and strategies.
  • Ability to quickly acquire necessary medical and scientific knowledge and skills through self-learning.
  • Clinical research experience.
  • Ability to understand written and spoken English and Japanese in the assigned therapeutic disease area and scientific interactions.
Responsibilities
  • Serve as Pfizer Japan's medical scientific point of contact for healthcare professionals, medical societies, regulators, academia, and other external stakeholders.
  • Maintain scientific standards, independence, and compliance in external medical and scientific activities and internal processes.
  • Provide and exchange medical and scientific information with medical institutions and stakeholders in the assigned area.
  • Increase understanding of the clinical and medical attributes of products to support their safe and efficacious use.
  • Contribute to local medical strategies and life-cycle clinical plans for inline and pipeline medicines and vaccines to address unmet medical needs and fill data gaps.
  • Contribute to medical strategy decisions for assigned products to ensure their safe, proper, and effective use.
  • Contribute to department and team goals, participate as a core member in cross-organizational projects, provide guidance, and support team members in collaboration with the line manager.
  • Identify unmet medical needs and healthcare disparities in assigned assets and therapeutic areas through advisory boards, scientific exchanges with healthcare professionals, and other relevant activities.
  • Create medical activity plans with senior Medical management to address identified needs and fill data gaps.
  • Develop and execute Customer Facing Medical Plans for assigned therapeutic areas and assets, including unbiased scientific communication, advisory board meetings, educational seminars, data-generation initiatives, medical-material creation, and scientific input.
  • Provide subject-matter expertise and scientific exchange, bringing insights into the organization to inform strategy.
  • Build scientific relationships through non-promotional exchanges with relevant stakeholders, including discussion of current research papers and follow-up on academic conference presentations.
  • Develop and maintain stakeholder maps for relevant healthcare professionals, medical societies, and external stakeholders.
  • Handle unsolicited medical requests and provide accurate, high-quality, unbiased information in accordance with Pfizer policies, while sharing customer viewpoints with Pfizer as appropriate.
  • Follow up on clinical investigator-sponsored research and medical grants in compliance with Pfizer policies.
  • Acquire and maintain extensive medical and pharmaceutical information in the assigned area.
  • Deliver medical-plan activities, including educational materials, real-world evidence, non-interventional studies, database studies, and registries in collaboration with the Health & Value team, and support timely publication of data.
  • Establish long-term peer-to-peer scientific relationships with leading healthcare professionals and specialists, including non-traditional partners and key decision makers.
  • Maintain cross-business-unit alignment on metrics.
  • Collect and analyze information and insights before stakeholder and healthcare-professional meetings.
  • Provide stakeholder and healthcare-professional feedback to relevant company departments and consolidate it into medical, public health, and healthcare insights.
  • Share medical-field issues with internal and external stakeholders to support evidence generation through constructive cross-functional partnerships.
  • Apply health-literacy and cultural-awareness principles to patient-centric medical communications and deliverables.
  • Provide expert and healthcare-professional feedback on product life-cycle strategies to relevant company divisions and departments.
  • Collect and analyze unmet medical needs and seek solutions with cross-functional colleagues.
  • Provide scientific input for scientific meetings and materials.
  • Provide medical education programs with and to relevant stakeholders.
  • Conduct activities in compliance with Japanese Ministry of Health, Labour and Welfare guidelines for prescription drug sales information activities and applicable policies, guidelines, and regulations.
  • Gather and report safety information for Pfizer products in accordance with applicable laws, regulations, and Pfizer policy, and attend safety-reporting training as appropriate.
  • As needed, collaborate with Japan Medical leadership, global Medical Affairs members, and relevant functions to identify unmet medical needs and candidate therapies for potential medical interventions in Japan, maintaining confidentiality.
  • As needed, respond rapidly to critical supply issues from the medical perspective, including communications with academic societies and regulatory authorities.
Desired Qualifications
  • An MD with clinical experience; board certification is preferred.
  • A PhD in life science.
  • Work experience in Medical Affairs, Development, and/or Research.
  • Scientific publication experience.
  • Medical science liaison experience.
  • A minimum TOEIC score of 730.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.